Posts

Mirum and First Tracks report positive trial results

on
Mirum Pharmaceuticals said its Phase 3 EXPAND trial of LIVMARLI (maralixibat) met its primary endpoint in patients with cholestatic pruritus linked to ultra-rare liver diseases, including biliary atresia. The 52-person study also met all five prespecified secondary endpoints. Mirum plans to submit results to the FDA in the first half of 2027. First Tracks Biotherapeutics reported positive top-line results from Cohort 1 of its Phase 1b celiac disease trial of ANB033. In a 32-participant gluten-challenge study, treatment significantly reduced gluten-related intestinal damage versus placebo and helped prevent symptom worsening. No serious treatment-related adverse events were reported. Both updates are early steps, not proof of regulatory approval: First Tracks expects data from its second cohort in Q1 2027, while Mirum’s reported results would support a potential label expansion. Sources: Release Details News Releases - First Tracks Biotherapeutics, Inc ir.firsttracksbio.co...

Rubedo reports lower skin epigenetic-age measure and inflammatory markers after four weeks of RLS-1496

on

Beacon presents positive pivotal VISTA results for laru-zova

on

BMS’s admilparant succeeds at lower dose in pivotal IPF trial

on

HCW Biologics targets first-half 2027 IND filing for solid-tumor candidate

on

Rasonque subtype results raise a caveat, but analysts stay bullish

on

Aspen and Bambusa disclose plans for biotech IPOs

on

GSK plans $800M-plus Pennsylvania R&D and manufacturing hub

on

Appio takes over as interim CEO after Saunders leaves Bausch + Lomb

on

Asahi Kasei’s AiCuris buyout pays off with FDA approval for HOVILPRI

on

Rasonque mutation-level data point to a possible opening for competing pancreatic-cancer treatments

on

Early outlook on Merck’s tulisokibart in HS

on

GSK expands collaboration with Chai Discovery after lab tests

on